Company News
Glatiramer Acetate Officially Ships to Global Markets
The first international shipment marks a substantive step in Hybio's global commercialization strategy.
Hybio has completed an international shipment of its self-developed glatiramer acetate injection, marking continued progress in overseas commercialization.
The milestone connects product development, global registration, quality management, and commercial supply execution.
Built for international supply
Global market entry requires consistent product quality, dependable production planning, and close coordination across regulatory and supply teams.
Hybio's integrated industrial platform is designed to preserve product knowledge through each of these stages.
